IMBCR Newsletter July 2014

There has been tremendous progress on multiple fronts at IMBCR. First, we have now clearly established that our new serum biomarker B-cell maturation antigen (BCMA) tracks the course of myeloma very accurately. BCMA is present on the surface of the malignant plasma cells in multiple myeloma. We have already shown that the protein is shed READ MORE

ASCO 2014

ASCO 2014: Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma